Thymopentin added to zidovudine in a randomized HIV trial
Randomized study in people · 1995
- What was studied
- 352 asymptomatic participants with 200–500 CD4 cells/µL randomized. Prior zidovudine exposure exceeded six months in 235 participants (mean 16 months in this group) and was six months or less in 117.
- Main finding
- AIDS or death after more than six months of prior AZT · 2 events with thymopentin versus 10 with placebo (p=0.024). The authors report a relative risk of 4.9 in the placebo-to-thymopentin direction (95% CI 1.1–22.2).
Reported findings and study design
Reported findings
Double-blind multicenter comparison of thymopentin 50 mg subcutaneously three times per week against placebo for up to 48 weeks. All participants continued zidovudine (AZT). The investigators analyzed outcomes by intention to treat and reported a statistically significant treatment-by-stratum interaction.
Population or model 352 asymptomatic participants with 200–500 CD4 cells/µL randomized. Prior zidovudine exposure exceeded six months in 235 participants (mean 16 months in this group) and was six months or less in 117.
Dose, route and schedule
Double-blind multicenter comparison of thymopentin 50 mg subcutaneously three times per week against placebo for up to 48 weeks. All participants continued zidovudine (AZT). The investigators analyzed outcomes by intention to treat and reported a statistically significant treatment-by-stratum interaction.
Protocol source ↗ · Original indexed abstract. It reports event counts and total strata sizes.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| AIDS or death after more than six months of prior AZT | 2 events with thymopentin versus 10 with placebo (p=0.024). The authors report a relative risk of 4.9 in the placebo-to-thymopentin direction (95% CI 1.1–22.2). | |
| AIDS or death after six months or less of prior AZT | 4 events with thymopentin versus 0 with placebo (p=0.11). | |
| Laboratory measures and tolerability | No between-group differences in CD4 counts, HIV p24 antigen or reported clinical and laboratory adverse experiences. |
Reported event counts by prior zidovudine exposure
| Prior zidovudine | Outcome | Thymopentin events | Placebo events | Reported p | Reported relative risk (95% CI) |
|---|---|---|---|---|---|
| More than 6 months (235 total) | AIDS or death | 2 | 10 | 0.024 | 4.9 (1.1–22.2) |
| More than 6 months (235 total) | AIDS-related complex, AIDS or death | 3 | 18 | 0.001 | 5.9 (1.7–20.0) |
| 6 months or less (117 total) | AIDS or death | 4 | 0 | 0.11 | — |
| 6 months or less (117 total) | AIDS-related complex, AIDS or death | 4 | 2 | 0.79 | — |
Relative risks shown are placebo versus thymopentin. Per-arm denominators within each stratum are unavailable in the abstract.
The clinical finding varied across prior-treatment groups and involved few events. The 1996 biomarker paper reanalyzed these same 352 participants. The trial predates modern combination antiretroviral treatment.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- The clinical finding varied across prior-treatment groups and involved few events. The 1996 biomarker paper reanalyzed these same 352 participants. The trial predates modern combination antiretroviral treatment.
Related publications may describe some of the same participants or experiments.
Source details
Original indexed abstract. It reports event counts and total strata sizes.
Sources checked
Added to the library
Citation
G. Goldstein, M. A. Conant, G. Beall, H. A. Grossman, J. E. Galpin, G. Blick, L. H. Calabrese, R. L. Hirsch, A. Fisher, P. Stampone. Thymopentin added to zidovudine in a randomized HIV trial Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 8(3), 279–288
Study source ↗ · DOI 10.1097/00042560-199503010-00009 · Bibliography entry · Link to this summary